Seres Therapeutics Strengthens Balance Sheet, Extends Cash Runway

Seres Therapeutics, Inc. has announced two transactions intended to strengthen its balance sheet and extend its projected operating cash runway into the first quarter of 2027. These actions include an agreement with Nestlé Health Science and a restructured lease agreement.

The company entered into an amendment to a prior asset purchase agreement with Nestlé Health Science, under which Nestlé will pay Seres $25 million in two equal installments in July and October 2026. This payment buys out potential future sales-based milestones for VOWST™. Seres previously sold the VOWST business to Nestlé Health Science in 2024. VOWST is the first orally administered microbiome-based therapeutic approved by the U.S. Food and Drug Administration for the prevention of recurrent Clostridioides difficile infection in adults.

Additionally, Seres has restructured its lease for a facility in Cambridge, Massachusetts. The amended lease significantly reduces the company's leased space, ongoing annual facility costs, and long-term lease obligations. Seres expects these measures to improve its financial flexibility and support its focused corporate strategy.

"We have taken meaningful actions to strengthen our balance sheet and extend our cash runway well into the first quarter of 2027," said Richard Kender, Executive Chair and Interim Chief Executive Officer of Seres. The company stated its intention to continue rigorous financial discipline while advancing its live biotherapeutic programs for inflammatory and immune diseases, including its SER-155 program.

As of March 31, 2026, Seres had $29.8 million in cash and cash equivalents. Based on the announced transactions and current operating plans, Seres expects to fund operations well into the first quarter of 2027. This projection excludes proceeds from potential future partnerships or other capital sources.